Dronedarone is a rhythm control medicine (antiarrhythmic drug) and has been approved by the U.S. Food and Drug Administration (FDA) in certain patients with atrial fibrillation since 2009. In addition, dronedarone:
- is well-tolerated
- is effective in preventing recurrent AFib
- has been shown to reduce cardiovascular hospitalization
- is safe
- post-hoc analyses suggest it performs well in persons with early AFib